A number of FDA-approved medications exist to treat the progression of AD pathophysiology (i.e., preventing amyloid beta or tau aggregation) or its symptoms (cholinesterase inhibitors, glutamate regulators, antipsychotic medication)3. This evidence concerns the gene MAPT and Alzheimer disease.